<DOC>
	<DOCNO>NCT02702427</DOCNO>
	<brief_summary>Invasive infection CMV Adenovirus , respond virostatic treatment treat virusspecific donor derive autologous virusspecific T-cells .</brief_summary>
	<brief_title>Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation ( HSCT ) treatment option several haematological disease . In spite substantial progress field , viral infection , mainly cytomegalovirus ( CMV ) adenovirus ( HAdV ) context delay immunoreconstitution remain life threatening complication . Weekly screen high-risk patient preemptive virostatic treatment become current strategy . Unfortunately , treatment virostatic drug associate substantial nephro- myelo-toxicity limited effectiveness . Human adenovirus ( HAdV ) cytomegalvirus ( CMV ) disseminate infection associate mortality rate 50 % -60 % despite virostatic treatment . All HSCT patient St. Anna Children 's Hospital undergo weekly viral quantitative PCR-screening HAdV CMV weekly PB FACS ( Fluorescence Activated Cell Sorter ) -Analysis accord local HSCT-diagnostic SOP ( Standard Operating Procedure ) day -7 day +100 Patients HAdV CMV viremia receive preemptive treatment either gancyclovir ( case isolate CMV-viremia ) Cidofovir ( case HAdV viremia combine HAdV/CMV infection ) . In case increase viremia ≥ 1log despite antiviral treatment two week stable 10E6 viral load absence virus specific T-cells recipient , treat physician check , patient eligible seVirus-T-cell infusion ( see inclusion criterion ) . Study Design : Mononuclear Donor-Cells peripheral blood ( 100 ml extra donation ) cryopreserved time-point HSCT . In case progredient viremia cell stimulate interleukin-15 peptide virus molecule , virusspecific T-Cells enrich 2-3 logs-teps potentially alloreactive cell dilute time . This new approach reduces risk graft-versus-host-disease ( GvHD ) enable infusion virus-specific T-cells also haploidentical donor .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Age timepoint HSCT ≤18 year undergo allogeneic stem cell transplantation Presence HAdV CMVspecific Tcells donor CMVspecific Tcells recipient pretransplant Stable ( ≥ 10E6 ) increase viremia despite antiviral treatment post HSCT Absence HAdV CMV specific T cell post HSCT Karnofsky / Lansky score &gt; 50 % Pregnancy exclude Informed study participation consent sign Infusion polyclonal monoclonal Tcell direct antibody within 28 day seVirus TCell infusion Multiple organ failure screeningtimepoint seVirus TCell infusion History GvHD Gr IIIIV actual GvHD Gr IIIIV Pregnancy Treatment granulocyte transfusion within last 72 hour Karnofsky / Lansky score &lt; 50 % Subject unwilling unable comply study procedure High dose treatment steroid ( ≥ 2mg/kg/d , methylprednisoneequivalent )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>viral infection post HSCT , virus-specific T-cells</keyword>
</DOC>